Given the profound impact of PD-1 and PD-L1 inhibitors on advanced NSCLC, many experts have paid great attention to investigating the potential role of ICIs in resectable NSCLC, and several undergoing clinical trials have reported promising results (8–11). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.